Everolimus in therapy of lung and gastrointestinal neuroendocrine tumors - comments on Radiant-4

Abstract

RADIANT-4 trail is the first multicentric international randomised phase III study confirming efficacy of mTOR inhibitor everolimus in progressive, advanced, well differentiated non-functioning neuroendocrine tumors of lung and gastrointestinal tract.

Keywords

• Everolimus
• RADIANT-4 trial
• neuroendocrine tumors of lung and gastrointestinal tract